Immunexpress Announces Presentations At The 45th Annual Society Of Critical Care Medicine Congress On The Utility Of SeptiCyte Lab
SEATTLE, Feb. 10, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data on the utility of SeptiCyte® Lab in both adult and pediatric populations to aid in the clinical assessment of sepsis in critical care patients will be presented at the upcoming 45th Annual Society of Critical Care Medicine Congress on Feb. 21-22 in Orlando, Fla.
Presentation Title: "Validation of a Novel Host Response Assay to Distinguish Sepsis from SIRS in Critically Ill Patients. Results from the Venus A Study"
Research Snapshot Theater Session: Sepsis 2
Presenter: Dr. Russell R. Miller, III
Abstract: 1002
Date: Sunday, Feb. 21
Time: 11:30 a.m. 12:30 p.m. EST
Location: Theater 1
Presentation Title: "Sensitive and Specific Diagnosis of Sepsis In Critically Ill Children Utilizing Host Gene Expression"
Research Snapshot Theater Session: Sepsis 5
Presenter: Dr. Jerry Zimmerman
Abstract: 1024
Date: Monday, Feb. 22
Time: 11:00 a.m. 12:00 p.m. EST
Location: Theater 1
Additional information may be found at http://www.sccm.org/Education-Center/Annual-Congress/Pages/default.aspx
Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Sepsis diagnostics today aim to identify the pathogen only and therefore have serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte® solution evaluates the host immune response to aid clinicians in quickly and accurately diagnosing sepsis.
About Immunexpress
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system the "host response." Detecting the host's septic immune response has the potential to identify sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.
Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.
Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunexpress-announces-presentations-at-the-45th-annual-society-of-critical-care-medicine-congress-on-the-utility-of-septicyte-lab-300217549.html
SOURCE Immunexpress, Inc.
